BRAF and cancer: Specifically, we selected dose–response data from the treatment of three BRAF-targeted drugs: i) Dabrafenib, ii) PLX-4720 and iii) SB590885 across multiple cancer cell lines from GDSC1 (comprising only skin cutaneous melanoma (SKCM) cell lines; N = 52) and GDSC2 (N = 279) datasets.